Aggressive Multi-Modality Treatment of Pancreatic Neuroendocrine Tumors (pNETs): Outcomes in Patients with Advanced Disease Abstract #1144

Introduction: pNETs carry the worst prognosis of all NETs, particularly when hepatic metastasis are present. We try to actively treat all patients referred.
Aim(s): We aimed to determine survival at 1, 3 & 5 years for pNETs treated with modern aggressive multimodal management and compare outcomes to previously published data.
Materials and methods: Data was analysed from a single centre, prospective database. 95 of 396 NET patients were identified as pNETs. 3 patients had incomplete records and were excluded. Outcomes were analysed using Kaplan-Meier, with death as the endpoint.
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: Damian Mayo

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1777 Tumour Size Is Not a Reliable Criterion for Resection of Patients with Non-Secreting Pancreatic Neuroendocrine Tumours: Results of an International, Multi-Centre, Operative Cohort
Introduction: Small pancreatic neuroendocrine tumours (pNETs) present a management dilemma between surveillance and resection.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Logan Mills
#1273 Tissue Prognostic Markers in Pancreatic Neuroendocrine Tumours
Introduction: Pancreatic neuroendocrine tumours (pNETs) are a rare, heterogeneous class of neoplasms, with a rising incidence. Prognosis is variable with 5-year survival as low as 16% in inoperable tumours.
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: Dr Jonathan Dunbar
Authors: Dunbar J, Tod J, Horne J, Armstrong T, ...
#1148 Ki67 as a Prognostic Marker in Neuroendocrine Tumours: A Systematic Review of the Literature and Quantitative Synthesis of 5 year Survival Data
Introduction: The ENETS guidelines classify Gastroenteropancreatic Neuroendocrine Tumours (GEP NETs) according to the histological assessment of tumour mitotic count or Ki67 labelling index (LI) on paraffin-embedded tissue, because proliferation rate has been shown to strongly correlate with prognosis. Since the guidelines were published, Ki67 has been established as the more reproducible measure, and further large case series have been reported.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr Judith Cave
Keywords: GEP-NET, prognosis, Ki67
#495 Risk Factors for Sporadic Pancreatic Neuroendocrine Tumors (PNETs): Updated Results From a Single-Center Case Control Study
Introduction: PNETs are uncommon and little is known about risk factors and association with other cancers.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Thorvardur Halfdanarson
#2250 Treatment Outcomes of Patients with Mixed Neuroendocrine Non-Neuroendocrine Neoplasms (MiNEN)
Introduction: Mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN) have been newly defined in the WHO 2017 classification. They are rare tumors, commonly treated in analogy to their non-neuroendocrine (nNE) or neuroendocrine (NE) component without systematic data regarding the optimal therapeutic strategy.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr. med. Leonidas Apostolidis